End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.15 USD | -2.54% | -3.36% | -43.63% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Capitalization 1 | 714.2 | 122.8 | 150.4 | 85.46 | - |
Enterprise Value (EV) 1 | 714.2 | 108.8 | 150.4 | 85.46 | 85.46 |
P/E ratio | -60.9 x | - | - | - | - |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | 0.49 x | 0.46 x | 0.21 x | 0.18 x |
EV / Revenue | - | 0.49 x | 0.46 x | 0.21 x | 0.18 x |
EV / EBITDA | - | -5.22 x | -5.83 x | -6.29 x | 47.6 x |
EV / FCF | - | -1.82 x | -3.68 x | -2.49 x | -4.17 x |
FCF Yield | - | -54.8% | -27.2% | -40.1% | -24% |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 73,249 | 74,421 | 73,749 | 74,313 | - |
Reference price 2 | 9.750 | 1.650 | 2.040 | 1.150 | 1.150 |
Announcement Date | 22-03-10 | 23-03-09 | 24-03-27 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net sales 1 | - | 252.5 | 324.2 | 412.5 | 482.8 |
EBITDA 1 | - | -23.54 | -25.8 | -13.58 | 1.797 |
EBIT 1 | - | -79.96 | -77.02 | -18.82 | -3.514 |
Operating Margin | - | -31.67% | -23.75% | -4.56% | -0.73% |
Earnings before Tax (EBT) | - | - | - | - | - |
Net income 1 | -10.93 | 1.657 | -83.07 | -50.37 | -36.22 |
Net margin | - | 0.66% | -25.62% | -12.21% | -7.5% |
EPS | -0.1600 | - | - | - | - |
Free Cash Flow 1 | - | -67.28 | -40.88 | -34.29 | -20.49 |
FCF margin | - | -26.65% | -12.61% | -8.31% | -4.24% |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 22-03-10 | 23-03-09 | 24-03-27 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | 64.98 | 71.42 | 76.19 | 80.22 | 82.04 | 85.79 | 95.16 | 102.5 | 107.1 | 107.8 |
EBITDA 1 | - | -6.68 | -4.641 | -7.929 | -6.941 | -5.35 | -6.252 | -5.642 | -3.144 | -1.687 | -3.109 |
EBIT 1 | - | -20.1 | -23.08 | -32.87 | -14.94 | -13.92 | -15.29 | -6.944 | -4.448 | -2.998 | -4.426 |
Operating Margin | - | -30.93% | -32.32% | -43.14% | -18.62% | -16.97% | -17.82% | -7.3% | -4.34% | -2.8% | -4.1% |
Earnings before Tax (EBT) | - | -2.698 | - | - | - | - | - | - | - | - | - |
Net income 1 | -5.453 | -2.674 | -9.502 | - | -16.9 | -17.42 | -18.75 | -14.67 | -12.4 | -10.94 | -12.36 |
Net margin | - | -4.12% | -13.3% | - | -21.06% | -21.23% | -21.86% | -15.42% | -12.1% | -10.22% | -11.46% |
EPS | -0.0600 | -0.0300 | - | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 22-08-09 | 22-11-09 | 23-03-09 | 23-05-10 | 23-08-08 | 23-11-08 | 24-03-27 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | - | 14 | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow 1 | - | -67.3 | -40.9 | -34.3 | -20.5 |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex 1 | - | 5.53 | 4.57 | 5.16 | 6.28 |
Capex / Sales | - | 2.19% | 1.41% | 1.25% | 1.3% |
Announcement Date | 22-03-10 | 23-03-09 | 24-03-27 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-43.63% | 85.46M | |
-14.92% | 84.68B | |
+13.30% | 81.12B | |
+11.62% | 29.4B | |
-12.71% | 16.73B | |
-3.06% | 16.36B | |
-2.63% | 14.92B | |
-31.75% | 11.77B | |
-1.42% | 11.72B | |
+27.44% | 11.71B |
- Stock Market
- Equities
- TOI Stock
- Financials The Oncology Institute, Inc.